Koncept i upotreba populacionih farmakokinetičkih i farmakokinetičko/farmakodinamičkih modela u razvoju leka i kliničkoj praksi
Sažetak
Usled čestih neuspeha u kliničkim ispitivanjima i posledično manjeg broja odobrenja novih lekova, potreba za poboljšanjem u razvoju lekova je u određenoj meri zadovoljena korišćenjem pristupa razvoja lekova zasnovanog na modelu. Farmakometrija predstavlja granu farmakologije koja kvantifikuje ponašanje leka, odgovor na terapiju i napredovanje bolesti na osnovu različitih modela (farmakokinetički - FK, farmakodinamički - FD, FK/FD modeli itd.) i simulacija. Regulatorna tela (Evropska agencija za lekove, Uprava za hranu i lekove) podstiču primenu modelovanja i simulacija u svrhu lakšeg donošenja odluka tokom svih faza razvoja lekova. Štaviše, identifikacija faktora koji doprinose varijabilnosti predstavlja osnovu za individualizaciju doze u rutinskoj kliničkoj praksi. Ovaj revijalni rad sumira trenutno znanje u vezi sa primenom farmakometrije u razvoju lekova i kliničkoj praksi sa fokusom na populacionu analizu.
Reference
Hill RG. Drug discovery and development: Technology in transition: Elsevier Health Sciences; 2012. 368 p.
Turner JR. New drug development: An introduction to clinical trials. New York: Springer; 2010. 256 p.
Salazar DE, Gormley G. Modern drug discovery and development. In: Robertson D, Williams G, editors. Clinical and translational science: Principles of human research. London: Elsevier; 2017. p. 719-43.
Marchenko OV, Katenka NV. Quantitative methods in pharmaceutical research and development: Concepts and applications: Springer; 2020. 445 p.
Kimko H, Pinheiro J. Model-based clinical drug development in the past, present and future: A commentary. Br J Clin Pharmacol. 2015;79(1):108-16.
Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, et al. Model-based drug development: A rational approach to efficiently accelerate drug development. Clin Pharmacol Ther. 2013;93(6):502-14.
U.S. Food and Drug Administration. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products 2004. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/critical-path-initiative.
Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther. 2007;81(2):213-21.
Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V, et al. Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications. AAPS J. 2005;7(3):E503-12.
Lee JY, Garnett CE, Gobburu JV, Bhattaram VA, Brar S, Earp JC, et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: A review of 198 submissions between 2000 and 2008. Clin Pharmacokinet. 2011;50(10):627-35.
Wang Y, Bhattaram AV, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: Impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol. 2008;48(2):146-56.
European Medicines Agency. Guideline on reporting the results of population pharmacokinetic analyses 2007. Available from: https://www.ema.europa.eu/en/reporting-results-population-pharmacokinetic-analyses.
U.S. Food and Drug Administration. Guidance for industry population pharmacokinetics 1999. Available from: https://www.fda.gov/media/71364/download.
U.S. Food and Drug Administration. Population pharmacokinetics guidance for industry; draft guidance 2019. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/population-pharmacokinetics.
EFPIA MID3 Workgroup, Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, et al. Good practices in model-informed drug discovery and development: Practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol. 2016;5(3):93-122.
U.S. Food and Drug Administration. Exposure-response relationships - study design, data analysis, and regulatory applications 2003. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exposure-response-relationships-study-design-data-analysis-and-regulatory-applications.
Gobburu JV. Pharmacometrics 2020. J Clin Pharmacol. 2010;50(9 Suppl):151S-7S.
Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol. 2009;49:291-301.
Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: A multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol. 2008;48(5):632-49.
Ette EI, Williams PJ. Pharmacometrics: The science of quantitative pharmacology. Hoboken: Wiley; 2007.
Xu Y, Kimko H. Pharmacometrics: A quantitative decision-making tool in drug development. In: Marchenko O, Katenka N, editors. Quantitative methods in pharmaceutical research and development. 1 ed: Springer; 2020. p. 71-104.
Lala M, Gobburu JV. Pharmacometrics: Concepts and applications to drug development. In: Kaplan B, Burckart GJ, Lakkis FG, editors. Immunotherapy in transplantation: Principles and practice. 1 ed: Wiley-Blackwell; 2012. p. 114-32.
Kim TH, Shin S, Shin BS. Model-based drug development: Application of modeling and simulation in drug development. J Pharm Investig. 2018;48(4):431-41.
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1(9):e6.
Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: Part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2014;3:e88.
Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives. Pharm Res. 1999;16(2):176-85.
Holford N. A time to event tutorial for pharmacometricians. CPT Pharmacometrics Syst Pharmacol. 2013;2:e43.
Aarons L. Population pharmacokinetics: Theory and practice. Br J Clin Pharmacol. 1991;32(6):669-70.
Ette EI, Williams PJ. Population pharmacokinetics II: Estimation methods. Ann Pharmacother. 2004;38(11):1907-15.
Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: Modelling and software. Clin Pharmacokinet. 2012;51(8):515-25.
Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411-59.
De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67 Suppl 1:5-16.
Duffull SB, Wright DF, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol. 2011;71(6):807-14.
Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: Metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):87-109.
Beal S SL, Boeckmann A, Bauer RJ. Nonmem user´s guides. Ellicott City: Icon Development Solutions; 1989-2018.
Monolix. 2020R1 version: Lixoft. Available from: https://lixoft.com/products/monolix/
Phoenix NLME. 8.3 version: Certara. Available from: https://www.certara.com/software/pkpd-modeling-and-simulation/phoenix-nlme/
The R project for statistical computing. R Core Team. Available from: https://www.r-project.org/
Pillai GC, Mentre F, Steimer JL. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn. 2005;32(2):161-83.
Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: An experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013;2:e51.
Owen JS, Fiedler-Kelly J. Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models. New Jersey: John Wiley & Sons; 2014. 320 p.
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: Introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.
Ette EI, Williams PJ. Population pharmacokinetics I: Background, concepts, and models. Ann Pharmacother. 2004;38(10):1702-6.
Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463-8.
Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17-20.
Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: Validation methods. Clin Pharmacokinet. 2012;51(9):573-90.
Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: Design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother. 2004;38(12):2136-44.
Bender G, Gosset J, Florian J, Tan K, Field M, Marshall S, et al. Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: Application of simulation to preclinical PK-PD study design. Pharm Res. 2009;26(10):2259-69.
Chen WJ, Zhou TY, Lu W. Population pharmacokinetics and its application in new drug research (abstract). Yao xue xue bao = Acta pharmaceutica Sinica. 2017;52(3):371-7.
Porzio S. Application of population pharmacokinetics for preclinical safety and efficacy studies. Bioanalysis. 2013;5(16):2053-69.
Holford N, Ma SC, Ploeger BA. Clinical trial simulation: A review. Clin Pharmacol Ther. 2010;88(2):166-82.
Bonate PL. Clinical trial simulation in drug development. Pharm Res. 2000;17(3):252-6.
Girard P. Clinical trial simulation: A tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol. 2005;96(3):228-34.
Aarons L, Karlsson MO, Mentre F, Rombout F, Steimer JL, van Peer A, et al. Role of modelling and simulation in phase I drug development. Eur J Pharm Sci. 2001;13(2):115-22.
Bellanti F, van Wijk RC, Danhof M, Della Pasqua O. Integration of PKPD relationships into benefit-risk analysis. Br J Clin Pharmacol. 2015;80(5):979-91.
Standing JF. Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Br J Clin Pharmacol. 2017;83(2):247-54.
Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C, Brewster M, Lum B, Bittner B. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacometrics Syst Pharmacol. 2014;3:e87, doi: 10.1038/psp.2013.63.
Wang YC, Wang Y, Schrieber SJ, Earp J, Thway TM, Huang SM, et al. Role of modeling and simulation in the development of novel and biosimilar therapeutic proteins. J Pharm Sci. 2019;108(1):73-7.
European Medicines Agency. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. 2007. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-role-pharmacokinetics-development-medicinal-products-paediatric-population_en.pdf
Suvarna V. Phase IV of drug development. Perspect Clin Res. 2010;1(2):57-60.
Farahani P, Levine M, Gaebel K, Thabane L. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: Evaluation of etanercept in rheumatoid arthritis. Can J Clin Pharmacol. 2005;12(3):e254-63.
Brzakovic B, Vucicevic K, Kovacevic SV, Miljkovic B, Prostran M, Martinovic Z, et al. Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach. Eur J Clin Pharmacol. 2014;70(2):179-85.
Jovanovic M, Sokic D, Grabnar I, Vovk T, Prostran M, Vucicevic K, et al. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. Eur J Pharm Sci. 2013;50(3-4):282-9.
Vucicevic K, Jovanovic M, Golubovic B, Kovacevic SV, Miljkovic B, Martinovic Z, et al. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. Eur J Clin Pharmacol. 2015;71(2):183-90.
Vucicevic K, Miljkovic B, Pokrajac M, Prostran M, Martinovic Z, Grabnar I. The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci. 2009;38(5):512-8.
Vucicevic K, Miljkovic B, Velickovic R, Pokrajac M, Mrhar A, Grabnar I. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. Ther Drug Monit. 2007;29(6):781-8.
Golubovic B, Vucicevic K, Radivojevic D, Kovacevic SV, Prostran M, Miljkovic B. Total plasma protein effect on tacrolimus elimination in kidney transplant patients-population pharmacokinetic approach. Eur J Pharm Sci. 2014;52:34-40.
Golubovic B, Vucicevic K, Radivojevic D, Kovacevic SV, Prostran M, Miljkovic B. Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients - population pharmacokinetic approach. J Med Biochem. 2019;38(3):323-31.
Golubovic B, Prostran M, Miljkovic B, Vucicevic K, Radivojevic D, Grabnar I. Population pharmacokinetic approach of immunosuppressive therapy in kidney transplant patients. Curr Med Chem. 2016;23(19):1998-2011.
Jovanović M, Vučićević K, Miljković B. Understanding variability in the pharmacokinetics of atypical antipsychotics-focus on clozapine, olanzapine and aripiprazole population models. Drug Metab Rev. 2020;52(1):1-18.
Holford N. Pharmacodynamic principles and target concentration intervention. Transl Clin Pharmacol. 2018;26(4):150-4.
Darwich AS, Polasek TM, Aronson JK, Ogungbenro K, Wright DFB, Achour B, et al. Model-informed precision dosing: Background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. Annu Rev Pharmacol Toxicol. 2021;61:225-45.
Polasek TM, Shakib S, Rostami-Hodjegan A. Precision dosing in clinical medicine: Present and future. Expert Rev Clin Pharmacol. 2018;11(8):743-6.
Polasek TM, Kirkpatrick CM, Rostami-Hodjegan A. Precision dosing to avoid adverse drug reactions. Ther Adv Drug Saf. 2019; 10:2042098619894147, doi: 10.1177/2042098619894147.
Wright DFB, Martin JH, Cremers S. Spotlight commentary: Model-informed precision dosing must demonstrate improved patient outcomes. Br J Clin Pharmacol. 2019;85(10):2238-40.
Holford N, Ma G, Metz D. TDM is dead. Long live TCI! Br J Clin Pharmacol. 2020; doi: 10.1111/bcp.14434.
Wicha SG, Martson AG, Nielsen EI, Koch BCP, Friberg LE, Alffenaar JW, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928-41.
Abdulla A, Edwina AE, Flint RB, Allegaert K, Wildschut ED, Koch BCP, et al. Model-informed precision dosing of antibiotics in pediatric patients: A narrative review. Front Pediatr. 2021;9:624639.
Charles B. Population pharmacokinetics: An overview. Australian Prescriber. 2014;37(6):210-3.
Uster DW, Stocker SL, Carland JE, Brett J, Marriott DJE, Day RO, et al. A model averaging/selection approach improves the predictive performance of model-informed precision dosing: Vancomycin as a case study. Clin Pharmacol Ther. 2021;109(1):175-83.
Sime FB, Roberts MS, Roberts JA. Optimization of dosing regimens and dosing in special populations. Clin Microbiol Infect. 2015;21(10):886-93.
Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-informed precision dosing at the bedside: Scientific challenges and opportunities. CPT Pharmacometrics Syst Pharmacol. 2018;7(12):785-7.
Kantasiripitak W, Van Daele R, Gijsen M, Ferrante M, Spriet I, Dreesen E. Software tools for model-informed precision dosing: How well do they satisfy the needs? Front Pharmacol. 2020;11:620.
Rybak MJ, Le J, Lodise T, Levine D, Bradley J, Liu C, et al. Executive summary: Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. J Pediatric Infect Dis Soc. 2020;9(3):281-4.
Grimsrud KN, Sherwin CM, Constance JE, Tak C, Zuppa AF, Spigarelli MG, et al. Special population considerations and regulatory affairs for clinical research. Clin Res Regul Aff. 2015;32(2):47-56.
Stillhart C, Vucicevic K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, et al. Impact of gastrointestinal physiology on drug absorption in special populations-an UNGAP review. Eur J Pharm Sci. 2020;147:105280.
Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017;109S:S22-S6.
Momper JD, Mulugeta Y, Burckart GJ. Failed pediatric drug development trials. Clin Pharmacol Ther. 2015;98(3):245-51.
Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-32.
Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941-52.
Germovsek E, Barker CI, Sharland M, Standing JF. Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful? Br J Clin Pharmacol. 2017;83(4):777-90.
Kos MK, Miksic M, Jovanovic M, Roskar R, Grosek S, Grabnar I. Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis. Eur J Pharm Sci. 2020;141:105095.
Kovacevic T, Miljkovic B, Kovacevic P, Dragic S, Momcicevic D, Avram S, et al. Population pharmacokinetic model of vancomycin based on therapeutic drug monitoring data in critically ill septic patients. J Crit Care. 2020;55:116-21.
Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, et al. Predicting optimal dihydroartemisinin-piperaquine regimens to prevent malaria during pregnancy for human immunodeficiency virus-infected women receiving efavirenz. J Infect Dis. 2018;217(6):964-72.
Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and Drug Administration's office of Clinical Pharmacology. J Pharm Sci. 2019;108(1):21-5.
Jones HM, Gardner IB, Watson KJ. Modelling and PBPK simulation in drug discovery. AAPS J. 2009;11(1):155-66.
Huang W, Nakano M, Sager J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic model of the CYP2D6 probe atomoxetine: Extrapolation to special populations and drug-drug interactions. Drug Metab Dispos. 2017;45(11):1156-65.
U.S. Food and Drug Administration. Physiologically based pharmacokinetic analyses - format and content guidance for industry 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry.
U.S. Food and Drug Administration. In vitro drug interaction studies - cytochrome p450 enzyme- and transporter-mediated drug interactions guidance for industry 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions.
European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation 2018. Available from: https://www.ema.europa.eu/en/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation.
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).